| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteosarcoma | 17 | 2020 | 158 | 3.070 |
Why?
|
| Bone Neoplasms | 13 | 2020 | 322 | 2.660 |
Why?
|
| Growth Differentiation Factor 2 | 27 | 2021 | 152 | 2.170 |
Why?
|
| Osteogenesis | 29 | 2021 | 242 | 2.140 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2021 | 111 | 2.000 |
Why?
|
| Cell Differentiation | 42 | 2021 | 1458 | 1.940 |
Why?
|
| Arthroplasty, Replacement, Hip | 5 | 2018 | 102 | 1.500 |
Why?
|
| Cell Proliferation | 29 | 2021 | 1578 | 1.130 |
Why?
|
| Stem Cells | 15 | 2017 | 351 | 1.070 |
Why?
|
| Signal Transduction | 31 | 2018 | 3241 | 1.030 |
Why?
|
| Wnt Proteins | 13 | 2017 | 123 | 0.970 |
Why?
|
| Osteoblasts | 10 | 2013 | 95 | 0.910 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2018 | 1197 | 0.890 |
Why?
|
| Bone Morphogenetic Proteins | 12 | 2013 | 126 | 0.870 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 2 | 2013 | 7 | 0.870 |
Why?
|
| S100 Proteins | 4 | 2015 | 50 | 0.850 |
Why?
|
| beta Catenin | 15 | 2019 | 251 | 0.840 |
Why?
|
| Mice | 63 | 2021 | 11352 | 0.830 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2020 | 126 | 0.810 |
Why?
|
| Mice, Nude | 22 | 2018 | 790 | 0.780 |
Why?
|
| Genetic Vectors | 13 | 2019 | 439 | 0.740 |
Why?
|
| HEK293 Cells | 24 | 2019 | 615 | 0.740 |
Why?
|
| Growth Differentiation Factors | 9 | 2018 | 57 | 0.740 |
Why?
|
| Deltoid Muscle | 1 | 2020 | 2 | 0.740 |
Why?
|
| Smooth Muscle Tumor | 1 | 2020 | 4 | 0.730 |
Why?
|
| Neoplasm Metastasis | 8 | 2013 | 1056 | 0.720 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 50 | 0.700 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 78 | 0.700 |
Why?
|
| Herpesvirus 4, Human | 1 | 2020 | 114 | 0.690 |
Why?
|
| Cell Cycle Proteins | 4 | 2015 | 388 | 0.670 |
Why?
|
| Femoral Nerve | 1 | 2018 | 7 | 0.660 |
Why?
|
| Cell Line, Tumor | 22 | 2018 | 2426 | 0.640 |
Why?
|
| Nerve Block | 1 | 2018 | 51 | 0.630 |
Why?
|
| Analgesia | 1 | 2018 | 57 | 0.630 |
Why?
|
| Adenoviridae | 15 | 2014 | 345 | 0.630 |
Why?
|
| Anesthetics, Local | 1 | 2018 | 76 | 0.620 |
Why?
|
| Animals | 73 | 2021 | 26582 | 0.600 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 413 | 0.590 |
Why?
|
| Cell Movement | 14 | 2018 | 758 | 0.580 |
Why?
|
| Reoperation | 2 | 2018 | 597 | 0.550 |
Why?
|
| Pain, Postoperative | 1 | 2018 | 240 | 0.550 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 243 | 0.540 |
Why?
|
| Anticoagulants | 1 | 2018 | 408 | 0.520 |
Why?
|
| Patient Readmission | 1 | 2018 | 329 | 0.500 |
Why?
|
| Humans | 96 | 2021 | 86617 | 0.500 |
Why?
|
| Antineoplastic Agents | 10 | 2020 | 2358 | 0.480 |
Why?
|
| RNA, Small Interfering | 5 | 2019 | 547 | 0.480 |
Why?
|
| Cell Line | 26 | 2021 | 2468 | 0.460 |
Why?
|
| Wnt Signaling Pathway | 5 | 2019 | 91 | 0.450 |
Why?
|
| Niclosamide | 3 | 2018 | 10 | 0.440 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2006 | 179 | 0.360 |
Why?
|
| Cytoskeletal Proteins | 5 | 2004 | 223 | 0.360 |
Why?
|
| Osteoblastoma | 1 | 2009 | 4 | 0.350 |
Why?
|
| Lung Neoplasms | 5 | 2015 | 2262 | 0.350 |
Why?
|
| Liver | 5 | 2017 | 1230 | 0.350 |
Why?
|
| RNA, Long Noncoding | 2 | 2021 | 102 | 0.340 |
Why?
|
| RNA Interference | 7 | 2019 | 369 | 0.330 |
Why?
|
| Receptors, Notch | 2 | 2019 | 120 | 0.330 |
Why?
|
| Gene Transfer Techniques | 6 | 2014 | 152 | 0.320 |
Why?
|
| Tissue Scaffolds | 3 | 2013 | 106 | 0.320 |
Why?
|
| Male | 28 | 2021 | 40958 | 0.320 |
Why?
|
| Hepatocytes | 3 | 2014 | 127 | 0.310 |
Why?
|
| Monensin | 2 | 2018 | 16 | 0.310 |
Why?
|
| Trans-Activators | 5 | 2004 | 429 | 0.310 |
Why?
|
| Neoplasm Invasiveness | 5 | 2015 | 552 | 0.300 |
Why?
|
| Adipogenesis | 3 | 2021 | 38 | 0.300 |
Why?
|
| Genetic Therapy | 5 | 2014 | 342 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 3 | 2017 | 746 | 0.290 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 1464 | 0.280 |
Why?
|
| Gene Expression | 6 | 2019 | 1284 | 0.270 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2017 | 71 | 0.270 |
Why?
|
| Antigens, Polyomavirus Transforming | 3 | 2018 | 47 | 0.270 |
Why?
|
| Ossification, Heterotopic | 2 | 2021 | 31 | 0.270 |
Why?
|
| Fibroblasts | 5 | 2018 | 729 | 0.260 |
Why?
|
| Transduction, Genetic | 3 | 2014 | 153 | 0.260 |
Why?
|
| Gene Expression Profiling | 8 | 2017 | 1384 | 0.260 |
Why?
|
| Apoptosis | 8 | 2018 | 1683 | 0.260 |
Why?
|
| Chondrocytes | 3 | 2014 | 60 | 0.260 |
Why?
|
| Dental Papilla | 2 | 2014 | 6 | 0.250 |
Why?
|
| Alkaline Phosphatase | 11 | 2021 | 132 | 0.250 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 184 | 0.250 |
Why?
|
| Female | 24 | 2021 | 44509 | 0.240 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2013 | 879 | 0.240 |
Why?
|
| Gene Expression Regulation | 8 | 2013 | 1920 | 0.240 |
Why?
|
| Chondrogenesis | 4 | 2021 | 26 | 0.240 |
Why?
|
| Phenotype | 6 | 2015 | 2378 | 0.240 |
Why?
|
| Embryonic Stem Cells | 2 | 2014 | 78 | 0.240 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 255 | 0.230 |
Why?
|
| Bone Morphogenetic Protein 2 | 4 | 2014 | 37 | 0.230 |
Why?
|
| DNA Transposable Elements | 2 | 2014 | 169 | 0.230 |
Why?
|
| Cartilage, Articular | 2 | 2014 | 67 | 0.230 |
Why?
|
| Receptors, Retinoic Acid | 4 | 2010 | 45 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2004 | 65 | 0.220 |
Why?
|
| Retinoid X Receptors | 4 | 2010 | 39 | 0.220 |
Why?
|
| Drug Synergism | 7 | 2018 | 303 | 0.220 |
Why?
|
| Cell Adhesion | 4 | 2010 | 420 | 0.220 |
Why?
|
| Tretinoin | 4 | 2010 | 126 | 0.220 |
Why?
|
| Aged | 9 | 2021 | 18402 | 0.220 |
Why?
|
| Neoplasm Transplantation | 4 | 2014 | 391 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2018 | 458 | 0.210 |
Why?
|
| Bone Regeneration | 3 | 2013 | 52 | 0.210 |
Why?
|
| Cell Division | 4 | 2014 | 696 | 0.210 |
Why?
|
| Mice, Inbred C3H | 7 | 2015 | 370 | 0.210 |
Why?
|
| Sarcoma | 2 | 2017 | 212 | 0.210 |
Why?
|
| Wnt3A Protein | 4 | 2015 | 23 | 0.200 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 2232 | 0.190 |
Why?
|
| Transfection | 6 | 2019 | 896 | 0.190 |
Why?
|
| Cells, Cultured | 11 | 2013 | 2818 | 0.190 |
Why?
|
| Neovascularization, Physiologic | 3 | 2017 | 133 | 0.190 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 916 | 0.190 |
Why?
|
| Wound Healing | 3 | 2015 | 344 | 0.190 |
Why?
|
| S100 Calcium Binding Protein A6 | 3 | 2015 | 12 | 0.190 |
Why?
|
| Lactams, Macrocyclic | 1 | 2020 | 14 | 0.180 |
Why?
|
| Benzoquinones | 1 | 2020 | 27 | 0.180 |
Why?
|
| Bone and Bones | 4 | 2011 | 265 | 0.180 |
Why?
|
| Colorectal Neoplasms | 3 | 2014 | 938 | 0.180 |
Why?
|
| Blotting, Western | 6 | 2013 | 782 | 0.180 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2020 | 46 | 0.180 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2016 | 44 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 273 | 0.180 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 744 | 0.180 |
Why?
|
| Middle Aged | 9 | 2018 | 25017 | 0.180 |
Why?
|
| Drug Interactions | 1 | 2020 | 248 | 0.170 |
Why?
|
| Analysis of Variance | 2 | 2018 | 912 | 0.170 |
Why?
|
| Transgenes | 3 | 2014 | 180 | 0.170 |
Why?
|
| Cell Cycle | 5 | 2021 | 502 | 0.170 |
Why?
|
| Down-Regulation | 4 | 2011 | 504 | 0.170 |
Why?
|
| Osteocytes | 2 | 2012 | 9 | 0.170 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 113 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2021 | 8477 | 0.170 |
Why?
|
| Rivaroxaban | 1 | 2018 | 12 | 0.170 |
Why?
|
| Hip Dislocation | 1 | 2018 | 10 | 0.170 |
Why?
|
| Enoxaparin | 1 | 2018 | 23 | 0.170 |
Why?
|
| Neoplasms | 3 | 2015 | 2898 | 0.170 |
Why?
|
| Dabigatran | 1 | 2018 | 24 | 0.170 |
Why?
|
| ErbB Receptors | 3 | 2018 | 485 | 0.170 |
Why?
|
| Umbilical Cord | 1 | 2018 | 40 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 7 | 2010 | 1041 | 0.160 |
Why?
|
| Viral Proteins | 2 | 2014 | 300 | 0.160 |
Why?
|
| Biomarkers | 7 | 2017 | 1718 | 0.160 |
Why?
|
| Angiotensin II | 1 | 2018 | 94 | 0.160 |
Why?
|
| Bupivacaine | 1 | 2018 | 45 | 0.160 |
Why?
|
| Gene Knockdown Techniques | 3 | 2021 | 236 | 0.160 |
Why?
|
| Niacinamide | 1 | 2018 | 116 | 0.160 |
Why?
|
| Warfarin | 1 | 2018 | 103 | 0.160 |
Why?
|
| Bone Diseases | 2 | 2011 | 54 | 0.160 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 114 | 0.160 |
Why?
|
| Odontogenesis | 2 | 2014 | 13 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2013 | 557 | 0.160 |
Why?
|
| PPAR gamma | 4 | 2012 | 66 | 0.160 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 154 | 0.150 |
Why?
|
| Spinal Fusion | 1 | 2018 | 85 | 0.150 |
Why?
|
| Fetus | 3 | 2013 | 226 | 0.150 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 148 | 0.150 |
Why?
|
| Aspirin | 1 | 2018 | 156 | 0.150 |
Why?
|
| Fibrosis | 1 | 2018 | 203 | 0.150 |
Why?
|
| Adult | 9 | 2020 | 25640 | 0.150 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 18 | 0.150 |
Why?
|
| Mebendazole | 1 | 2017 | 6 | 0.150 |
Why?
|
| Antinematodal Agents | 1 | 2017 | 7 | 0.150 |
Why?
|
| Postoperative Period | 1 | 2018 | 303 | 0.150 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2017 | 14 | 0.150 |
Why?
|
| Knee Joint | 1 | 2018 | 168 | 0.150 |
Why?
|
| Genes, Reporter | 6 | 2017 | 268 | 0.150 |
Why?
|
| Receptor, Notch1 | 1 | 2017 | 85 | 0.150 |
Why?
|
| Pain Measurement | 1 | 2018 | 321 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 589 | 0.140 |
Why?
|
| Melanocytes | 2 | 2017 | 56 | 0.140 |
Why?
|
| Epidermal Growth Factor | 2 | 2013 | 119 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 257 | 0.140 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2016 | 114 | 0.140 |
Why?
|
| Cell Culture Techniques | 2 | 2018 | 188 | 0.140 |
Why?
|
| DNA | 3 | 2014 | 1294 | 0.140 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 94 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2016 | 108 | 0.130 |
Why?
|
| Time Factors | 7 | 2015 | 5209 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 3 | 2007 | 301 | 0.130 |
Why?
|
| Anthelmintics | 1 | 2015 | 6 | 0.130 |
Why?
|
| Base Sequence | 5 | 2014 | 2330 | 0.130 |
Why?
|
| Length of Stay | 1 | 2018 | 700 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 4 | 2017 | 623 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2018 | 812 | 0.130 |
Why?
|
| Adolescent | 5 | 2017 | 8979 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 3 | 2014 | 937 | 0.130 |
Why?
|
| Up-Regulation | 6 | 2018 | 712 | 0.130 |
Why?
|
| Orthopedics | 1 | 2016 | 124 | 0.130 |
Why?
|
| Joint Diseases | 1 | 2015 | 49 | 0.120 |
Why?
|
| Logistic Models | 1 | 2018 | 1185 | 0.120 |
Why?
|
| Simian virus 40 | 1 | 2014 | 35 | 0.120 |
Why?
|
| Hexadimethrine Bromide | 1 | 2014 | 4 | 0.120 |
Why?
|
| Multipotent Stem Cells | 1 | 2014 | 19 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2019 | 534 | 0.120 |
Why?
|
| Virus Assembly | 1 | 2014 | 21 | 0.120 |
Why?
|
| Immediate-Early Proteins | 2 | 2006 | 164 | 0.120 |
Why?
|
| Cell Survival | 5 | 2015 | 969 | 0.120 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 25 | 0.120 |
Why?
|
| Prostatic Neoplasms | 3 | 2004 | 1721 | 0.120 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 242 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2018 | 426 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2015 | 195 | 0.120 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1823 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2013 | 302 | 0.120 |
Why?
|
| Protein Precursors | 1 | 2014 | 143 | 0.120 |
Why?
|
| Cell Line, Transformed | 4 | 2014 | 154 | 0.120 |
Why?
|
| Mesoderm | 2 | 2004 | 108 | 0.120 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2013 | 63 | 0.120 |
Why?
|
| Integrases | 3 | 2014 | 59 | 0.120 |
Why?
|
| Receptor Cross-Talk | 1 | 2013 | 33 | 0.120 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 1753 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 350 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 645 | 0.110 |
Why?
|
| Recombination, Genetic | 3 | 2014 | 439 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 123 | 0.110 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 86 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2014 | 254 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 163 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 222 | 0.110 |
Why?
|
| Janus Kinase 1 | 1 | 2012 | 15 | 0.110 |
Why?
|
| Melanoma | 1 | 2017 | 454 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 144 | 0.110 |
Why?
|
| STAT Transcription Factors | 1 | 2012 | 18 | 0.110 |
Why?
|
| Bone Morphogenetic Protein 6 | 3 | 2007 | 10 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2012 | 42 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 621 | 0.110 |
Why?
|
| Cloning, Organism | 1 | 2012 | 19 | 0.110 |
Why?
|
| DNA Primers | 2 | 2013 | 543 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2010 | 1014 | 0.110 |
Why?
|
| Luciferases | 3 | 2010 | 118 | 0.110 |
Why?
|
| Growth Hormone | 1 | 2012 | 97 | 0.110 |
Why?
|
| HCT116 Cells | 4 | 2019 | 151 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2021 | 2207 | 0.100 |
Why?
|
| Endoplasmic Reticulum | 1 | 2013 | 250 | 0.100 |
Why?
|
| Models, Biological | 5 | 2020 | 1749 | 0.100 |
Why?
|
| Pluripotent Stem Cells | 2 | 2009 | 31 | 0.100 |
Why?
|
| Cell Lineage | 5 | 2012 | 273 | 0.100 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2010 | 4 | 0.100 |
Why?
|
| Benzylisoquinolines | 1 | 2010 | 3 | 0.100 |
Why?
|
| Factor VIII | 1 | 2010 | 7 | 0.100 |
Why?
|
| Hemophilia A | 1 | 2010 | 8 | 0.100 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2010 | 33 | 0.100 |
Why?
|
| Acyltransferases | 1 | 2010 | 41 | 0.100 |
Why?
|
| Intestines | 1 | 2014 | 411 | 0.100 |
Why?
|
| Activin Receptors, Type I | 1 | 2010 | 12 | 0.100 |
Why?
|
| CCN Intercellular Signaling Proteins | 1 | 2010 | 3 | 0.100 |
Why?
|
| Growth and Development | 1 | 2010 | 12 | 0.090 |
Why?
|
| Heart | 1 | 2013 | 539 | 0.090 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2007 | 11 | 0.090 |
Why?
|
| Child | 3 | 2011 | 6926 | 0.090 |
Why?
|
| Injections, Intramuscular | 2 | 2007 | 62 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 5 | 2012 | 305 | 0.090 |
Why?
|
| Ginsenosides | 1 | 2010 | 123 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 1075 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2013 | 673 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 1052 | 0.090 |
Why?
|
| Myoblasts | 1 | 2009 | 31 | 0.090 |
Why?
|
| Culture Media, Conditioned | 4 | 2014 | 104 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 143 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2020 | 114 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2018 | 1106 | 0.080 |
Why?
|
| Humerus | 1 | 2008 | 31 | 0.080 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 1937 | 0.080 |
Why?
|
| Femoral Neoplasms | 1 | 2008 | 24 | 0.080 |
Why?
|
| Embryo, Mammalian | 3 | 2014 | 207 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 427 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2009 | 270 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2009 | 234 | 0.080 |
Why?
|
| Kidney | 3 | 2018 | 1241 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2015 | 1047 | 0.080 |
Why?
|
| Bone Development | 1 | 2008 | 34 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 927 | 0.080 |
Why?
|
| Bone Morphogenetic Protein 3 | 1 | 2007 | 6 | 0.080 |
Why?
|
| Achilles Tendon | 1 | 2007 | 15 | 0.080 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2007 | 25 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 165 | 0.080 |
Why?
|
| Tensile Strength | 1 | 2007 | 79 | 0.070 |
Why?
|
| Calcification, Physiologic | 3 | 2013 | 33 | 0.070 |
Why?
|
| Smad Proteins | 3 | 2013 | 39 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2007 | 70 | 0.070 |
Why?
|
| Gene Silencing | 3 | 2014 | 172 | 0.070 |
Why?
|
| Genetic Engineering | 1 | 2007 | 114 | 0.070 |
Why?
|
| X-Ray Microtomography | 2 | 2021 | 80 | 0.070 |
Why?
|
| Disease | 1 | 2007 | 90 | 0.070 |
Why?
|
| Young Adult | 3 | 2017 | 5974 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 639 | 0.070 |
Why?
|
| Prognosis | 1 | 2014 | 3675 | 0.070 |
Why?
|
| Rats | 4 | 2014 | 3990 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7990 | 0.070 |
Why?
|
| Transcription, Genetic | 3 | 2008 | 1135 | 0.070 |
Why?
|
| Fracture Healing | 1 | 2005 | 34 | 0.060 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 3 | 2009 | 23 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 592 | 0.060 |
Why?
|
| Tetracycline | 1 | 2004 | 13 | 0.060 |
Why?
|
| Smad4 Protein | 2 | 2019 | 23 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 2436 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2013 | 316 | 0.060 |
Why?
|
| Vaginal Fistula | 1 | 2003 | 5 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2601 | 0.060 |
Why?
|
| Cell Separation | 2 | 2014 | 196 | 0.060 |
Why?
|
| Choristoma | 2 | 2013 | 68 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2008 | 689 | 0.060 |
Why?
|
| Protein Engineering | 1 | 2004 | 140 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 6501 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2004 | 157 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2004 | 252 | 0.050 |
Why?
|
| Bone Matrix | 2 | 2013 | 18 | 0.050 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 183 | 0.050 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 232 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2014 | 679 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2005 | 1538 | 0.050 |
Why?
|
| Zebrafish Proteins | 1 | 2003 | 144 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3357 | 0.050 |
Why?
|
| Injections, Intra-Articular | 1 | 2021 | 27 | 0.050 |
Why?
|
| Piperazines | 1 | 2003 | 272 | 0.050 |
Why?
|
| Cisplatin | 2 | 2017 | 612 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 1961 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2021 | 66 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 2019 | 646 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2013 | 692 | 0.050 |
Why?
|
| Retinoic Acid Receptor alpha | 2 | 2010 | 18 | 0.050 |
Why?
|
| Extremities | 2 | 2013 | 165 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2003 | 370 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 263 | 0.040 |
Why?
|
| Wnt1 Protein | 2 | 2013 | 24 | 0.040 |
Why?
|
| Risk Factors | 2 | 2021 | 5417 | 0.040 |
Why?
|
| Neomycin | 1 | 1998 | 7 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 90 | 0.040 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2018 | 4 | 0.040 |
Why?
|
| Transposon Resolvases | 1 | 2018 | 7 | 0.040 |
Why?
|
| Disease Progression | 2 | 2015 | 1531 | 0.040 |
Why?
|
| Joint Dislocations | 1 | 2018 | 27 | 0.040 |
Why?
|
| United States | 3 | 2017 | 6665 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1998 | 110 | 0.040 |
Why?
|
| Karyotyping | 1 | 1998 | 250 | 0.040 |
Why?
|
| Hip Prosthesis | 1 | 2018 | 34 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2018 | 50 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2018 | 82 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1998 | 348 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 108 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2018 | 237 | 0.040 |
Why?
|
| Desmosomes | 2 | 1994 | 10 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 128 | 0.040 |
Why?
|
| Liver Regeneration | 1 | 2017 | 32 | 0.040 |
Why?
|
| Pancreas | 1 | 2018 | 239 | 0.040 |
Why?
|
| Mammals | 1 | 2019 | 227 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 214 | 0.040 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2016 | 8 | 0.040 |
Why?
|
| Antiparasitic Agents | 1 | 2016 | 8 | 0.040 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 73 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2016 | 22 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 65 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2014 | 498 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 54 | 0.040 |
Why?
|
| United Kingdom | 1 | 2016 | 164 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 204 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2015 | 35 | 0.030 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2015 | 27 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 98 | 0.030 |
Why?
|
| Peptostreptococcus | 1 | 2015 | 3 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2015 | 43 | 0.030 |
Why?
|
| Historically Controlled Study | 1 | 2015 | 5 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 125 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 526 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 113 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 115 | 0.030 |
Why?
|
| Gossypol | 1 | 2014 | 6 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 103 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 2015 | 393 | 0.030 |
Why?
|
| Dependovirus | 1 | 2014 | 33 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 532 | 0.030 |
Why?
|
| Subcutaneous Tissue | 1 | 2014 | 10 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2014 | 39 | 0.030 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2014 | 15 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 156 | 0.030 |
Why?
|
| Adenoviridae Infections | 1 | 2014 | 15 | 0.030 |
Why?
|
| Odontoblasts | 1 | 2014 | 7 | 0.030 |
Why?
|
| Glycogen | 1 | 2014 | 59 | 0.030 |
Why?
|
| Cytokines | 1 | 2018 | 776 | 0.030 |
Why?
|
| S100 Calcium-Binding Protein A4 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Acetylation | 1 | 2014 | 121 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2013 | 37 | 0.030 |
Why?
|
| Intermediate Filaments | 1 | 1993 | 16 | 0.030 |
Why?
|
| Cadherins | 1 | 1994 | 151 | 0.030 |
Why?
|
| Maleimides | 1 | 2013 | 29 | 0.030 |
Why?
|
| Lithium | 1 | 2013 | 59 | 0.030 |
Why?
|
| Keratins | 1 | 1993 | 63 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2014 | 51 | 0.030 |
Why?
|
| Vimentin | 1 | 1993 | 44 | 0.030 |
Why?
|
| Durapatite | 1 | 2013 | 28 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2013 | 137 | 0.030 |
Why?
|
| Protein Binding | 2 | 2010 | 1456 | 0.030 |
Why?
|
| Subrenal Capsule Assay | 1 | 2013 | 5 | 0.030 |
Why?
|
| Protein Stability | 1 | 2013 | 99 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2013 | 62 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1239 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 456 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 178 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2016 | 403 | 0.030 |
Why?
|
| Polyesters | 1 | 2013 | 41 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 146 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 2013 | 77 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 85 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2016 | 444 | 0.030 |
Why?
|
| Regeneration | 1 | 2014 | 143 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2013 | 90 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 2062 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 2 | 2004 | 425 | 0.030 |
Why?
|
| Estradiol | 1 | 2013 | 252 | 0.030 |
Why?
|
| Estrogens | 1 | 2013 | 200 | 0.030 |
Why?
|
| Perfusion | 1 | 2013 | 203 | 0.030 |
Why?
|
| Transcriptome | 1 | 2017 | 580 | 0.030 |
Why?
|
| PAX3 Transcription Factor | 1 | 2012 | 11 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2015 | 394 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 2378 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1994 | 371 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2012 | 50 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 3030 | 0.030 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 38 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2012 | 79 | 0.030 |
Why?
|
| Rabbits | 1 | 2013 | 636 | 0.030 |
Why?
|
| Histones | 1 | 2014 | 311 | 0.030 |
Why?
|
| Indoles | 1 | 2013 | 318 | 0.030 |
Why?
|
| Polymers | 1 | 2013 | 202 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 736 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2012 | 175 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 2010 | 11 | 0.020 |
Why?
|
| Gentian Violet | 1 | 2010 | 10 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 40 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 4 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 263 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Implants, Experimental | 1 | 2010 | 16 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2010 | 62 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 253 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2010 | 37 | 0.020 |
Why?
|
| Activin Receptors, Type II | 1 | 2010 | 9 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 303 | 0.020 |
Why?
|
| RNA | 2 | 2004 | 560 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2010 | 135 | 0.020 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 53 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 131 | 0.020 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 2009 | 23 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2009 | 24 | 0.020 |
Why?
|
| Epirubicin | 1 | 2009 | 14 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2009 | 12 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 262 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 49 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2014 | 628 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 363 | 0.020 |
Why?
|
| Lipids | 1 | 2010 | 269 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 322 | 0.020 |
Why?
|
| Binding Sites | 2 | 2007 | 1098 | 0.020 |
Why?
|
| Panax | 1 | 2010 | 170 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 204 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2008 | 26 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2010 | 268 | 0.020 |
Why?
|
| Osteopontin | 1 | 2008 | 47 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 295 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 291 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 468 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2009 | 288 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 1565 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 468 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 379 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2007 | 72 | 0.020 |
Why?
|
| Adipocytes | 1 | 2008 | 155 | 0.020 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2006 | 5 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2007 | 122 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 50 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2006 | 133 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 1860 | 0.020 |
Why?
|
| Wnt3 Protein | 1 | 2004 | 13 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2004 | 14 | 0.020 |
Why?
|
| Desmoplakins | 2 | 1994 | 7 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2009 | 1924 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 1219 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 2004 | 72 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1981 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2010 | 3611 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 3092 | 0.010 |
Why?
|
| Acetabulum | 1 | 2003 | 28 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2003 | 126 | 0.010 |
Why?
|
| Bacteria | 1 | 2007 | 447 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 2003 | 111 | 0.010 |
Why?
|
| Benzamides | 1 | 2003 | 229 | 0.010 |
Why?
|
| Bone Density | 1 | 2003 | 209 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 280 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 813 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 1074 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 1139 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 645 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 777 | 0.010 |
Why?
|
| Mutation | 1 | 2010 | 3967 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2003 | 556 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1208 | 0.010 |
Why?
|
| Desmogleins | 1 | 1994 | 2 | 0.010 |
Why?
|
| gamma Catenin | 1 | 1994 | 7 | 0.010 |
Why?
|
| Desmocollins | 1 | 1994 | 3 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1994 | 108 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1994 | 281 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1993 | 94 | 0.010 |
Why?
|
| Genes, myc | 1 | 1993 | 39 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1993 | 205 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1994 | 428 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1993 | 1376 | 0.000 |
Why?
|